Gilead Sciences controversies
Controversies tied to this brand in public sources. A listing is not a finding of fault.
2022
Dispute over 340B contract-pharmacy restrictions
AIDS Healthcare Foundation publicly accused Gilead of unlawfully restricting access to certain medicines through 340B contract pharmacies and used the term “Greediad” in advocacy advertising. The supplied source documents the organization’s allegations and campaign, not a final legal determination.
2019
U.S. government sues Gilead over PrEP patent rights
Lawsuit filed
In a legal dispute involving Gilead Sciences, the U.S. Department of Health and Human Services filed a lawsuit concerning patent rights to Truvada and Descovy for HIV prevention. The suit asserts that the government owns the relevant PrEP patents. These claims are allegations made in the litigation and do not constitute a court determination. The event concerns a patent dispute over HIV prevention drugs and the asserted ownership of PrEP-related patents.
Company response
Denial — Gilead
In response, Gilead said the government’s patent claims were “invalid.”
Source excerpt
The lawsuit, filed Wednesday in U.S. District Court for the District of Delware, alleges that CDC researchers began studying the preventive use of HIV treatment drugs — like tenofovir, or TDF, and emtricitabine, FTC, the two compounds in a Truvada tablet — as early as 1998, before Gilead sought a patent.
Crucially, the lawsuit alleges that the government owns the PrEP patent for both Truvada and Descovy, Gilead’s next generation PrEP approved last month, setting up the possibility that both HIV prevention drugs could see drastic price reductions.
In response, Gilead said the government’s patent claims were “invalid.”